FDA PCAC July 2026: What 7 peptides under review mean for compounders
A buyer's briefing on BPC-157, TB-500, KPV, MOTs-C, Emideltide, Semax, and Epitalon — what changes, what doesn't, and how to prepare your sourcing pipeline.
Published May 16, 2026 · 6 min read · By PeptideXpo Regulatory Team
On April 15, 2026, the FDA announced that the Pharmacy Compounding Advisory Committee (PCAC) will convene on July 23–24, 2026 to discuss whether seven specific peptides should be added to the 503A bulks list for use by compounding pharmacies.
What's on the table
The PCAC will evaluate the following peptides and proposed indications:
| Peptide | Proposed indication |
|---|---|
| BPC-157 (free base + acetate) | Ulcerative colitis |
| KPV (free base + acetate) | Wound healing and inflammatory conditions |
| TB-500 (free base + acetate) | Wound healing |
| MOTs-C (free base + acetate) | Obesity and osteoporosis |
| Emideltide (free base + acetate) | Opioid withdrawal, chronic insomnia, narcolepsy |
| Semax (free base + acetate) | Cerebral ischemia, migraine, trigeminal neuralgia |
| Epitalon (free base + acetate) | Insomnia |
Why this matters
If the FDA accepts PCAC's recommendation to add any of these peptides to the 503A bulks list, compounding pharmacies could legally use them to compound patient-specific formulations — subject to the standard 503A requirements (USP/NF monograph, FDA-registered manufacturing facility, valid Certificate of Analysis).
That has three practical implications for sourcing teams:
- **Quality bar rises.** A bulks-list peptide must come from an FDA-registered facility with a valid COA. Your sourcing pipeline needs documentation depth, not just pricing.
- **Demand will consolidate.** Suppliers without auditable QA systems will be filtered out of compounding pharmacy procurement. The grey middle of "research-only / look the other way" disappears for these seven SKUs.
- **Stability and traceability become deal-breakers.** Compounding pharmacies must be able to demonstrate provenance for every batch. Lot-specific COA + sequence + MS reports become the standard ask, not an upgrade.
What we're doing at PeptideXpo
Independent of how PCAC votes, we already operate under bulks-list-aligned controls for BPC-157, TB-500, KPV, MOTs-C, Semax, and Epitalon. Each shipment ships with:
- Batch-specific Certificate of Analysis (third-party verified)
- HPLC chromatogram + mass-spec report
- Sequence verification on request
- LAL endotoxin + microbial limits for injectable-route applications
- Stability data on request (accelerated and long term)
What to expect after July 24
PCAC recommendations are advisory; the FDA will issue its decision in the following months. Whether or not the seven peptides are formally added to the 503A bulks list, the quality of documentation buyers demand has already structurally shifted. Suppliers without the paper trail will not survive the next two procurement cycles.
If you'd like to see a sample COA for any of the seven peptides on the PCAC agenda, request one through our quote form — we'll respond within 12 hours.